• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

CalmiGo Donates Exhalers to Help Survivors of Terrorist Attacks in Israel Cope with Anxiety and PTSD

by Syed Hamza Sohail 11/13/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • CalmiGo, a developer of the first and only drug-free device that empowers people suffering from anxiety, PTSD, and panic attacks with immediate relief, announces that the company donated 1200 portable exhalers to the victims of the terrorist attacks in Israel to help calm anxiety and alleviate symptoms of PTSD.
  • The donations were made possible due to the help of the non-profit organization, Reim, that provides urgent medical aid to Israel, as well as other generous donors.

Helping Civilians Cope with PTSD

Currently, numerous individuals throughout Israel are experiencing extreme anxiety and trauma from the attacks and there is a country-wide shortage of mental health professionals to address these sudden conditions. In an effort to assist the country recover emotionally from the attacks, CalmiGo is aiming to distribute their devices by using a triage method along with collaborating with healthcare professionals to ensure those most impacted receive the devices first.

Because of the shortage of healthcare professionals, drug-free devices aimed to relieve anxiety are invaluable to the recovery process of the victims since it does not require constant evaluation by a therapist, as medication mandates.

CalmiGo, a company with offices in New York and Israel, developed a scientifically proven and drug-free device that empowers people of all ages suffering from anxiety, stress, PTSD, or panic attacks to effortlessly manage their symptoms. The CalmiGo device is developed with patented technology that combines sensors and machine learning to learn a users’ breathing patterns in real time. The device provides guidance and feedback to help extend the length of exhalation between breathing cycles to activate the parasympathetic system, which counteracts the “fight or flight” response that one experiences in an anxiety attack. The device also incorporates grounding, a scientifically proven technique for treating anxiety and trauma, that involves activating four senses: sight, smell, sound, and touch. It does this with light cues to regulate breathing, embedded scents, as well as vibration.

“In light of the surge in anxiety and trauma cases in Israel right now, we wanted to make sure that we sent our devices to Israel to provide relief and intervention as soon as possible to those who are suffering,” says Adi Wallach, Chief Executive Officer at CalmiGo. ““To reduce the severity of symptoms in the long term, we know that it is critical to provide intervention as soon as possible after a traumatic event. With the help of our donors we are able to send our devices there shortly after the attacks. Our hearts are with all of the victims during this time.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |